ReviewCurrent opinion in immunology2011
Sialoside-based pattern recognitions discriminating infections from tissue injuries.
Review in Current opinion in immunology, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04317040 (A Randomized, Double-blind, Placebo-controlled, Multi-site, Phase III Study to Evaluate the Safety and Efficacy of CD24Fc in COVID-19 Treatment), which is not on this map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
A Randomized, Double-blind, Placebo-controlled, Multi-site, Phase III Study to Evaluate the Safety and Efficacy of CD24Fc in COVID-19 Treatment
Who cites it
15 citing papers in PubMed, 27 citations in OpenAlex.
- Targeting CD24/Siglec-10 signal pathway for cancer immunotherapy: recent advances and future directions.Cancer immunology, immunotherapy : CII · 2024Review
- Targeting CD24 in Cancer Immunotherapy.Biomedicines · 2023Review
- Impact of Siglecs on autoimmune diseases.Molecular aspects of medicine · 2023Review
- The biological roles of CD24 in ovarian cancer: old story, but new tales.Frontiers in immunology · 2023Review
- CD24-Siglec axis is an innate immune checkpoint against metaflammation and metabolic disorder.Cell metabolism · 2022Article
- CD24: A Novel Target for Cancer Immunotherapy.Journal of personalized medicine · 2022Review
- Complementary Experimental Methods in Genetics Open Up New Avenues of Research to Elucidate the Pathogenesis of Periodontitis.Advances in experimental medicine and biology · 2022Article
- A population of innate myelolymphoblastoid effector cell expanded by inactivation of mTOR complex 1 in mice.eLife · 2017Article
- Biological roles of glycans.Glycobiology · 2017Review
- The Inflammatory Role of Platelets via Their TLRs and Siglec Receptors.Frontiers in immunology · 2015Review
- Article
- Endometriosis, a disease of the macrophage.Frontiers in immunology · 2013Article
- Siglecs as sensors of self in innate and adaptive immune responses.Annals of the New York Academy of Sciences · 2012Review
- Siglecs and immune regulation.Annual review of immunology · 2012Review
- Macrophages in injured skeletal muscle: a perpetuum mobile causing and limiting fibrosis, prompting or restricting resolution and regeneration.Frontiers in immunology · 2011Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
Abstract
Recognition of pathogens-associated molecular patterns (PAMPs) by Toll-like receptors (TLRs), NOD-like receptors (NLRs) and RIG-I-like receptors (RLR) plays a critical role in protecting host against pathogens. In addition, TLR and NLR also recognize danger-associated molecular patterns (DAMPs) to initiate limited innate immune responses. While innate immune response to DAMPs may be important for tissue repairs and wound healing, it is normally well controlled to avoid autoimmune destruction. Recent data support a role for sialoside-based pattern recognition by members of the Siglec family to attenuate innate immunity. In particular, since CD24-Siglec 10/G interaction selectively dampens host response to DAMPs but not PAMPs, this sialoside-based pattern recognition may serve as a foundation to discriminate PAMPs from DAMPs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.